PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH CISPLATIN (CDDP) ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Takahashi, S.

Ura, T. ^{[1
]}

Nakano, K.

Chin, K.

Yokoyama, M.

Hatake, K.

Yokota, T. ^{[1
]}

Shitara, K. ^{[1
]}

Muro, K. ^{[1
]}

Aoyama, T.

机构：

[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：110 / 110

页数：1

共 50 条

[41] A phase I study of NC-6004, a micellar formulation of cisplatin, in combination with gemcitabine in Japanese patients with advanced solid tumors
Hamaguchi, Tetsuya
Doi, Toshihiko
Shitara, Kohei
Iwasa, Satoru
Shimada, Yasuhiro
Harda, Mitsunori
Naito, Kenichiro
Hayashi, Naoto
Masada, Atsuhiro
Ohtsu, Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
Sanborn, Sharon L.
Gibbons, Joseph
Krishnamurthi, Smitha
Brell, Joanna M.
Dowlati, Afshin
Bokar, Joseph A.
Nock, Charles
Horvath, Nancy
Bako, Jacob
Remick, Scot C.
Cooney, Matthew M.
INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 453 - 460
[43] Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours
Nadja E. Schoemaker
I. E. L. M. Kuppens
Wim W. Ten Bokkel Huinink
Patricia Lefebvre
Jos H. Beijnen
Sylvie Assadourian
Ger-Jan Sanderink
Jan H. M. Schellens
Cancer Chemotherapy and Pharmacology, 2005, 55 : 263 - 270
[44] Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
Sharon L. Sanborn
Joseph Gibbons
Smitha Krishnamurthi
Joanna M. Brell
Afshin Dowlati
Joseph A. Bokar
Charles Nock
Nancy Horvath
Jacob Bako
Scot C. Remick
Matthew M. Cooney
Investigational New Drugs, 2009, 27 : 453 - 460
[45] Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours
Schoemaker, NE
Kuppens, IELM
Huinink, WWT
Lefebvre, P
Beijnen, JH
Assadourian, S
Sanderink, GJ
Schellens, JHM
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (03) : 263 - 270
[46] A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors
Soria, Jean-Charles
Sessa, Christina
Perotti, A.
Massard, Christophe
Armand, Jean-Pierre
Lassau, Nathalie
Farace, Francoise
Borghi, Elsa
Gianni, Luca
CANCER RESEARCH, 2008, 68 (09)
[47] Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
Chu, Quincy
Mita, Alain
Forouzesh, Bahram
Tolcher, Anthony W.
Schwartz, Gary
Nieto, Antonio
Soto-Matos, Arturo
Alfaro, Vicente
Lebedinsky, Claudia
Rowinsky, Eric K.
CLINICAL CANCER RESEARCH, 2010, 16 (09) : 2656 - 2665
[48] Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Tan, Antoinette R.
Rubin, Eric H.
Walton, Diana C.
Shuster, Dale E.
Wong, Y. Nancy
Fang, Fang
Ashworth, Simon
Rosen, Lee S.
CLINICAL CANCER RESEARCH, 2009, 15 (12) : 4213 - 4219
[49] Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
Kerbusch, T
Groenewegen, G
Mathôt, RAA
Herben, VMM
Huinink, WWT
Swart, M
Ambaum, B
Rosing, H
Jansen, S
Voest, EE
Beijnen, JH
Schellens, J
BRITISH JOURNAL OF CANCER, 2004, 90 (12) : 2268 - 2277
[50] Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
T Kerbusch
G Groenewegen
R A A Mathôt
V M M Herben
W W ten Bokkel Huinink
M Swart
B Ambaum
H Rosing
S Jansen
E E Voest
J H Beijnen
J H M Schellens
British Journal of Cancer, 2004, 90 : 2268 - 2277

← 1 2 3 4 5 →